A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

Recruiting

Phase 1

Phase 2

Valemetostat Tosylate & PembrolizumabA Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

Sponsor:

Daiichi Sankyo

Code:

NCT06644768

Conditions

Non-small Cell Lung Cancer

Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

valemetostat tosylate

pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-28. This information was provided to ClinicalTrials.gov by Daiichi Sankyo on 2024-11-14.